# Oral Clofarabine Study in Patients With Myelodysplastic Syndrome

> **NCT00299156** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 65 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** Clofarabine

## Key facts

- **NCT ID:** NCT00299156
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2015-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00299156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00299156, "Oral Clofarabine Study in Patients With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00299156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*